AGMB (AgomAb Therapeutics NV) FCF Yield %: -9.41 (As of Jul. 12, 2026)


AGMB AgomAb Therapeutics NV AGMB
14 GF Score
Price $13.08
! 1 Warning Sign
View Full Analysis

What is AgomAb Therapeutics NV FCF Yield %?

AgomAb Therapeutics NV AGMB +0.85% 14 FCF Yield % is -9.41 as of Jul. 12, 2026. GuruFocus rates AGMB with a GF Score™ of 14/100. The stock has 1 warning sign investors should review. Among 1,409 Biotechnology companies, AgomAb Therapeutics NV ranks worse than 50.18% on this metric.

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, AgomAb Therapeutics NV's Trailing 12-Month Free Cash Flow is $-60.59 Mil, and Market Cap is $644.19 Mil. Therefore, AgomAb Therapeutics NV's FCF Yield % for today is -9.41%.

The historical rank and industry rank for AgomAb Therapeutics NV's FCF Yield % or its related term are showing as below:

AGMB' s FCF Yield % Range Over the Past 10 Years
Min: -9.41   Med: 0   Max: 0
Current: -9.41

AGMB's FCF Yield % is ranked worse than
50.18% of 1409 companies
in the Biotechnology industry
Industry Median: -9.4 vs AGMB: -9.41

AgomAb Therapeutics NV's FCF Margin % for the quarter that ended in Dec. 2025 was 0.00%.

AgomAb Therapeutics NV FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

AgomAb Therapeutics NV FCF Yield % Related Terms

AgomAb Therapeutics NV FCF Yield % Historical Data

* Premium members only.

The historical data trend for AgomAb Therapeutics NV's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AgomAb Therapeutics NV FCF Yield % Chart

AgomAb Therapeutics NV Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
FCF Yield %
0.00 0.00 0.00 0.00 0.00

AgomAb Therapeutics NV Quarterly Data
Dec21 Dec22 Dec23 Dec24 Sep25 Dec25
FCF Yield % Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

AGMB vs DNA, ACRS, RLMD: FCF Yield % Comparison

For the Biotechnology subindustry, AgomAb Therapeutics NV's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AgomAb Therapeutics NV FCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AgomAb Therapeutics NV's FCF Yield % distribution charts can be found below:

* The bar in red indicates where AgomAb Therapeutics NV's FCF Yield % falls into.


AGMB
14GF Score
AgomAb Therapeutics NV AGMB
FCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AgomAb Therapeutics NV FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

AgomAb Therapeutics NV's FCF Yield % for the fiscal year that ended in Dec. 2025 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-60.592 / 0
=N/A%

AgomAb Therapeutics NV's annualized FCF Yield % for the quarter that ended in Dec. 2025 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=0 * 4 / 0
=N/A%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Yield % →
What does a FCF Yield % of -9.41 mean?
AgomAb Therapeutics NV (AGMB) has a FCF Yield % of -9.41 as of Jul. 12, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on AgomAb Therapeutics NV and its competitors. According to the industry distribution chart, AgomAb Therapeutics NV ranks #707 out of 1409 companies in the Biotechnology industry, placing it in the top 50.2%.
Is AgomAb Therapeutics NV's FCF Yield % too high?
AgomAb Therapeutics NV's current FCF Yield % is -9.41. Based on the distribution chart, AgomAb Therapeutics NV ranks #707 out of 1409 companies in the Biotechnology industry, which is below the industry midpoint. Overall, AgomAb Therapeutics NV has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does AgomAb Therapeutics NV's FCF Yield % compare to DNA and ACRS?
According to the Biotechnology industry distribution chart, AgomAb Therapeutics NV ranks #707 out of 1409 companies for FCF Yield %. This places AgomAb Therapeutics NV in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on AgomAb Therapeutics NV and its competitors. AgomAb Therapeutics NV's current FCF Yield % is -9.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AgomAb Therapeutics NV stock overvalued right now?
AgomAb Therapeutics NV (AGMB) has a current FCF Yield % of -9.41. The current FCF Yield % is -9.41. AgomAb Therapeutics NV's overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For AgomAb Therapeutics NV (AGMB), the current FCF Yield % is -9.41 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

AgomAb Therapeutics NV Business Description

Address 1/6 Posthoflei, Antwerp, BEL, 2600
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.
14GF Score

Get the complete analysis for AGMB

FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.08
Price